A new research looking into a potential therapy for persons with monkeypox is being led by the group behind the COVID-19 therapies' world-renowned RECOVERY trial. The research has been ordered and paid for by the National Institute for Health and Care Research (NIHR). Now that the first sufferers have been enlisted.
The smallpox virus family includes monkeypox, which has historically been uncommon outside of west and central Africa. However, an epidemic was discovered in the UK in May of this year, and cases thereafter started to show in several other non-African nations. Monkeypox was classified as a Public Health Emergency of International Concern by the World Health Organization on July 23, 2018. A rash with painful blisters is one of the typical signs of monkeypox, which can spread widely or only affect a specific area of the body. Fever, a sore muscle, and swollen lymph nodes are among more symptoms that may appear. Without treatment, monkeypox often resolves, although it may take several weeks and, incredibly infrequently, lead to life-threatening complications.
Although smallpox immunizations may lower the likelihood of contracting monkeypox, there are presently no proven therapies to hasten the disease's recovery in individuals who become ill. The effectiveness and safety of tecovirimat, an antiviral medication initially designed for smallpox, will be examined in the placebo-controlled randomised trial of tecovirimat in non-hospitalized monkeypox patients (PLATINUM) research.
The drug tecovirimat, commonly known as TPOXX, stops the virus from spreading outside of affected cells. The Medicines and Health Products Regulatory Agency (MHRA) granted its licence earlier this year for the treatment of monkeypox in light of encouraging findings from preliminary animal studies and proof of its safety in healthy human volunteers. Currently, it is used to treat individuals who have been hospitalised to the hospital with serious sequelae from monkeypox. However, there haven't been any clinical studies to yet to verify if the medication will speed up the disease's recovery in monkeypox sufferers.
Sir Martin Landray, Professor of Medicine & Epidemiology at Oxford Population Health, and Sir Peter Horby, Joint Chief Investigators of the Randomised Evaluation of COVID-19 (RECOVERY) trial, are leading PLATINUM. Sir Martin Landray is Professor of Medicine & Epidemiology at Oxford Population Health and Professor of Emerging Infections and Global Health at the University of Oxford. Additionally, professionals with experience in the clinical evaluation and laboratory analysis of human monkeypox infections in the UK are contributing to the study from the University of Liverpool, Chelsea and Westminster Hospital NHS Foundation Trust, and UK Health Security Agency.
According to Professor Sir Peter Horby, a monkeypox infection can be upsetting and even hazardous. We need conclusive proof that tecovirimat is safe and effective for the benefit of existing and future patients worldwide who have been diagnosed with monkeypox. Although the preliminary statistics on tecovirimat are encouraging, a randomised clinical study will provide us the amount of proof we need to confidently treat patients. That proof will come from PLATINUM.
Professor Lucy Chappell, Chief Executive of the NIHR and Chief Scientific Adviser at the Department of Health and Social Care said: ‘This study is a very important next step towards looking at treatments for monkeypox for those being outside of hospital. It’s crucial that we invest in developing, refining and evaluating treatments for this disease. We have commissioned this research to show the sense of and seriousness with which the health research community is collectively approaching this issue.
The experiment will be conducted by a group that includes the prestigious RECOVERY team, led by Sir Peter Horby, whose world-class work had a significant influence on patient outcomes throughout the COVID-19 epidemic. The thoroughness and reliability of this study will guarantee that the conclusions are generally accepted and will enable us to advance in the evaluation of monkeypox therapies.
Participants in PLATINUM will be assigned at random to either a matching placebo therapy or a 14-day course of 600 mg tecovirimat twice daily. PLATINUM will be a community-based study, as opposed to RECOVERY, which enrolled hospital patients, with participants receiving the medication or a placebo in their own homes. Following clinical evaluation and test confirmation of monkeypox infection as part of routine NHS clinical treatment, eligible participants will be determined. At least 500 people from all around the UK are expected to participate in the study.
The research will evaluate the rate at which skin and mucosal lesions heal in order to determine whether tecovirimat aids patients in recovering more quickly. Additionally, it will evaluate how long it takes for throat and lesion swabs to test negative for the monkeypox virus as well as the percentage of patients who need to be hospitalised because of illness-related problems.
Maggie Throup, Minister of Public Health, stated: "This government-funded study is a crucial step toward discovering a remedy that will hasten the recovery of patients who have monkeypox."
This new monkeypox therapy study, which is being led by the same specialists that devised ground-breaking patient therapies for the COVID-19 RECOVERY trial, will examine how well the antiviral tecovirimat works to treat the illness.
We urge everyone who is eligible to come forward when called and report any symptoms to NHS 111 since vaccinations continue to be our strongest line of defence against the spread of monkeypox.
When you are sick and in agony, you are willing to try anything, but you do want to know if it will work or not, according to Harun Tulunay, a training and volunteer coordinator for Positively UK, a nonprofit that assists people living with HIV from Shoreditch, London. My physicians offered me tecovirimat when I was receiving treatment for monkeypox at the Royal Free London hospital. Even though they said there were no studies on its effectiveness, I insisted on taking it even though my health hadn't improved for days or even weeks. And for the first time, I saw a change in my health and an improvement in how I felt.
"This study will allow patients who are not in hospitals to understand how tecovirimat works, what they may expect, and the time period of the rehabilitation process," the patient said. "I don't want anybody else to get as terribly ill as I was. Knowing if there is a cure for monkeypox may also assist to ease any fear associated with it.
Following an open request for ideas, the NIHR awarded PLATINUM a £3.7 million grant. SIGA Technologies Inc. is supplying tecovirimat and a placebo as a control.
You must be logged in to post a comment.